DeutschNewstral
Article
dailyherald.com on 2016-03-25 14:16
Jury: Gilead owes Merck $200M in damages over drug patents
Related news
Jury: Gilead owes Merck $200M in damages over drug patentsneworleanscitybusiness.com
Jury: Gilead Owes Merck $200M in Damages Over Drug Patentsmemphisdailynews.com
Balm for Gilead: Unclean Hands Render Patents Unenforceablejdsupra.com- MMerck shares dip after surprise patent loss to Gileadmarketwatch.com
Gilead, Merck collaborate to develop long-acting HIV treatmentThe Jerusalem Post (JPost.com)
Gilead, Merck pause trial of once-a-week HIV drug combobizjournals.com- BMerck and Gilead Are Joining Forces on a Long-Acting HIV Therapybarrons.com
- Aiming at HIV treatments that last for months, Gilead aligns with Merckbizjournals.com
- BMerck and Gilead Sciences Sign Deals to Aid India's Covid-19 Fightbarrons.com
PatentsArkansas Online- Smartphone Wars – The Last Jury: Samsung Owes $539M for Infringing Apple’s Patentsjdsupra.com
- Four Additional IPRs Filed by Merck Challenging The Johns Hopkins University Pembrolizumab Patentsjdsupra.com
- Merck Files Four IPRs Challenging The Johns Hopkins University Pembrolizumab Patentsjdsupra.com
- Biotech giant Gilead pours more than $200M into foundation for community gifts, employee matches and 'health justice'bizjournals.com
N.J. mall sues restaurant for $2.8M, says eatery owes back rent and damagesnj.com- CJudge Dismisses $200M Damages Claim in AT&T Crypto Hack Lawsuitcoindesk.com
Judge Dismisses $200M Damages Claim in SIM-Swap Crypto Lawsuit Against AT&Tnews.bitcoin.com- LBiotechnology Market 2021-2026 Size and Share, Recent Enhancements and Regional Analysis | Key Companies: Johnson & Johnson, Roche, Pfizer, Merck, Sanofi, AstraZeneca, Gilead, CELGENE CORPORATION, …liverpoolstudentmedia.com
- LBreakthrough Therapy Designation Market 2021-2026 Size and Share, Recent Enhancements and Regional Analysis | Key Companies: Pfizer, Takeda, Eisai, Exelixis, Jazz Pharmaceuticals, Merck, Gilead, El…liverpoolstudentmedia.com
- Patent Judgments and Awards - Merck Ordered to Pay $14 Million in Attorneys’ Fees to Rival Gilead After a Patent Infringement Trial Involving Hepatitis C Drugsjdsupra.com